Trial intelligence / Profile preview

ELAD in severe acute alcoholic hepatitis with Lille score failure

2013-001884-21Phase 3Terminated

Sponsor: Vital Therapies, Inc.
Start: Jun 2013
Countries: 1

Overview

Phase 3, randomised, open-label trial of ELAD in alcoholic hepatitis (AH) (2 arms), sponsored by Vital Therapies, Inc. Primary endpoint: Overall survival. Started Jun 2013; status: terminated.

Drugs

ELAD

Conditions

alcoholic hepatitis (AH)

Beyond the preview

Go deeper on 2013-001884-21.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2013-001884-21.